Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
Cancer Treatment Reviews · 2024-11 · 130 · 102826
DOI: 10.1016/j.ctrv.2024.102826 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-11. Verfasst von Xinlin Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Qingdao Cancer Institute, Qingdao 266071, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Neoplasms, Epitopes. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 201 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Human epidermal growth factor receptor-2 (HER2) is overexpressed in various solid tumor types, acting as an established therapeutic target. Over the last three decades, the fast-paced development of diverse HER2-targeted agents, notably marked by the introduction of the antibody-drug conjugate (ADC), yielding substantial improvements in survival rates. However, resistance to anti-HER2 treatments continues to pose formidable challenges. The complex structure and dynamic dimerization properties of HER2 create significant hurdles in the development of novel targeted therapeutics. In this review, we synthesize the latest insights into the structural intricacies of HER2 and present an unprecedented overview of the epitope characteristics of HER2-targeted antibodies and their derivatives. Furthermore, we delve into the correlation between anti-HER2 antibody binding epitopes and their respective functions, with a particular focus on their efficacy against resistant tumors. In addition, we highlight the potential of emerging anti-HER2 agents that target specific sites or non-overlapping epitopes, poised to transform the therapeutic landscape for HER2-positive tumors in the foreseeable future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Qingdao Cancer Institute, Qingdao 266071, China.
- Qingdao Municipal Center for Disease Control and Prevention, Qingdao Institute of Preventive Medicine, Qingdao 266033, China.
- The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Qingdao Cancer Institute, Qingdao 266071, China. Electronic address: liangbing518@hotmail.com.
- The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Qingdao Cancer Institute, Qingdao 266071, China; School of Life Sciences, Tsinghua University, Beijing 100084, China. Electronic…
Förderung
- National Natural Science Foundation of China
- Shandong Province Natural Science Foundation
Zitieren
APA
Liu, X., Song, Y., Cheng, P., Liang, B., & Xing, D. (2024). Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. Cancer Treatment Reviews, 130, 102826. https://doi.org/10.1016/j.ctrv.2024.102826
Vancouver
Liu X, Song Y, Cheng P, Liang B, Xing D. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. Cancer Treatment Reviews. 2024;130:102826. doi:10.1016/j.ctrv.2024.102826
BibTeX
@article{Liu2024,
author = {Liu, Xinlin and Song, Yunlong and Cheng, Panpan and Liang, Bing and Xing, Dongming},
title = {Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {130},
pages = {102826},
doi = {10.1016/j.ctrv.2024.102826}
}
EUVIMED